Education
About Us
Working with TipRanks
Follow Us
Rezolute, Inc. (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
$2.72
-$0.34(-6.35%)
At close: 4:00 PM EST
$2.72
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)11.79M
Market Cap
$252.22M
Enterprise Value$821.43M
Total Cash (Recent Filing)$152.19M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Feb 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding92,727,530
10 Day Avg. Volume5,211,656
30 Day Avg. Volume11,791,859
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap3.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.68K
Enterprise Value/Ebitda-10.13
Forecast
1Y Price Target
$6.29Price Target Upside131.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Patient Benefit And RetentionAll trial completers entered the open‑label extension and several children discontinued other therapies to use ersodetug as monotherapy, indicating meaningful clinical benefit and strong patient willingness to continue treatment.
Pharmacology And Biomarker EvidenceBiomarker and pharmacologic data show ersodetug modulates the insulin receptor and reduces insulin signaling versus placebo, supporting clear biological activity that could translate into clinical benefit.
Regulatory Engagement And Development StrategyBreakthrough Therapy Designation combined with active engagement with the FDA and a revised Phase 3 design for tumor patients could create a clearer regulatory pathway and improve the chances of a robust approval strategy.
Bears Say
Financing And Dilution RiskThe company has no product revenue and is likely to need additional capital, creating dilution and financing risks that could pressure the stock.
Placebo And Study EffectA high placebo or study effect driven by intensive glucose monitoring likely obscured the drug's measurable benefit, complicating interpretation of pivotal trial results.
Reproducibility Of EfficacyPhase 3 efficacy did not fully match earlier Phase 2 results on continuous glucose monitoring, creating uncertainty about whether the observed benefits are reproducible in broader populations.
Rezolute News
RZLT FAQ
What was Rezolute, Inc.’s price range in the past 12 months?
Rezolute, Inc. lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute, Inc.’s market cap?
Rezolute, Inc.’s market cap is $252.22M.
When is Rezolute, Inc.’s upcoming earnings report date?
Rezolute, Inc.’s upcoming earnings report date is Feb 11, 2026 which is in 26 days.
How were Rezolute, Inc.’s earnings last quarter?
Rezolute, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Rezolute, Inc. overvalued?
According to Wall Street analysts Rezolute, Inc.’s price is currently Undervalued.
Does Rezolute, Inc. pay dividends?
Rezolute, Inc. does not currently pay dividends.
What is Rezolute, Inc.’s EPS estimate?
Rezolute, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Rezolute, Inc. have?
Rezolute, Inc. has 92,727,530 shares outstanding.
What happened to Rezolute, Inc.’s price movement after its last earnings report?
Rezolute, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went up 12.083%.
Which hedge fund is a major shareholder of Rezolute, Inc.?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.29 (131.09% Upside)
$6.29 (131.09% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $206.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.56%
12-Months-Change
Fundamentals
Return on Equity
-59.23%
Trailing 12-Months
Asset Growth
28.56%
Trailing 12-Months
Company Description
Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$6.29
▲(131.09% Upside)
Technical Analysis
Ownership Overview
11.34% Insiders
39.98% Mutual Funds
34.12% Other Institutional Investors
2.84% Public Companies and Individual Investors